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 The rabbit, because of its large eyes, ease of handling,
and cost effectiveness, has become a standard ophthalmic ani-
mal model for many surgical experiments, such as glaucoma
filtration surgery (GFS), as well as for the development of
new devices and medical therapies. Over the last five years,
microarrays, which can simultaneously evaluate changes in
gene expression of thousands of genes and are unparalleled in
their utility as a discovery tool, have been extensively used to
identify the molecular mechanisms of disease. Microarrays
are commercially available for the most common animal mod-
els. However, there is no microarray for the rabbit. Further-
more, there is little rabbit sequence in public databases from
which a microarray could be developed. In this paper we re-
port the sequencing of rabbit tissues and the development of
two rabbit microarrays. To test the biological validity of these
microarrays as a research tool, we performed GFS on rabbits
and compared the results of this study to other GFS and wound-
healing studies.
METHODS
Rabbit eye cDNA library construction:  Eight- to nine-week-
old, New Zealand white rabbits were obtained from Myrtle’s
Rabbitry (Thompsons Station, TN). Animals were treated ac-
cording to the ARVO Statement for the Use of Animals in
Ophthalmic and Vision Research and in compliance with in-
stitutional animal use and care guidelines. Eyes from two adult
rabbits were dissected and separated into two tissue groups:
anterior (cornea, conjunctiva, and iris) and posterior (retina
and sclera). Two separate cDNA libraries were constructed
using a procedure descibed in reference [1]. Briefly, total RNA
was extracted from tissue using RNAzol (Tel-Test Inc.,
Friendswood, TX) and Poly (A)+ RNA was isolated using an
oligo-dT cellulose affinity column. An aliquot of the RNA was
run on a denaturing gel, and quality was assessed by the pres-
ence of a smooth, mRNA-shaped curve of an appropriate range
of fragment size. Oligo-dT primed cDNA was synthesized at
Bioserve Biotechnology (Laurel, MD) using the Superscript
II system (Invitrogen, Carlsbad CA). The cDNA was run over
a Sephacryl S-500 HR column (Invitrogen) to fractionate
cDNA larger than 500 bp prior to being directionally cloned
in NotI/SalI sites in the pCMVSPORT6 vector (Invitrogen).
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matrix.
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164cDNA sequencing:  Methods for sequencing and
bioinformatic analysis are described in detail elsewhere [1,2].
Briefly, randomly picked clones were sequenced from the 5'
and 3' ends at the NIH Intramural Sequencing Center (NISC).
Grouping and identification of sequence tags (GRIST) were
used to analyze and assemble the data [2]. Clusters of se-
quences were also examined using SeqMan II (DNAstar,
Madison, WI) to check assembly of clusters and to examine
alternative transcripts. Sequences are available through
NEIBank.
Chip fabrication:  cDNA sequences from the new rabbit
eye libraries were combined with available rabbit sequences
from the National Center for Biotechnology Information
(NCBI) dbEST database. Paracel Transcript Assembler (PTA;
Paracel Inc., Pasadena, CA), which performs a series of se-
quence cleaning, chimera sequence identification, sequence
clustering, and sequence assembly steps, was used to gener-
ate a set of nonredundant sequences (contigs) [3]. For each
contig, a homology search was performed using the BLASTX
and BLASTN application of Paracel BLAST version 1.5.6
(Paracel Inc.) against the NCBI NR and NT databases, respec-
tively. The e-value threshold was set at e-4.
BLAST results were parsed and stored in BlastQuest [4],
a SQL database, developed by ICBR that facilitates the man-
agement of BLAST results and GeneOntology Consortium
(GO) [5] term browsing. AssemblyFilter software, also de-
veloped by ICBR, was used to query the top 100 BLAST hits
for each contig against the NCBI Gene database, which con-
tains annotation information, including gene function, based
on GO terms and metabolic pathway association based on
GenMAPP and KEGG pathway database maps [6]. The GO
terms and pathway information associated with the lowest e-
value and consistent between NR and NT search were assigned
to the query assembly. In cases where two contigs mapped to
the same gene, the contig assembled from the smaller number
of sequences was eliminated to minimize gene redundancy
within the entire set of contigs. Finally, AssemblyFilter and
ESTScan [7] were used to determine the sequence orienta-
tion.
Contigs were submitted to Agilent Technologies (Palo
Alto, CA), where a number of probes were designed for each
contig with the company’s software. Multiple probes were
designed for each contig and quality scores, ranging from 1-4,
accompanied each designed probe. Due to limited space, we
chose to only include one probe per contig and probes with
one of the two highest quality scores on the array. Unfortu-
nately, not all the contigs with high quality probes that were
designed could fit on the array. All probes with homology to a
sequence in the NR database were placed on the arrays. The
remainder of the space on the arrays was filled with probes
for which we could not find a homologous sequence. Custom
arrays were manufactured on glass slides on which 60-base
oligonucleotide probes were synthesized in situ with a non-
contact printer. Two separate rabbit arrays were manufactured
in the eight-pack format (eight individually hybridizable 1.9K
arrays per piece of glass). The first set covered 1,577 genes
obtained from anterior tissue, while the second set covered
1,577 genes expressed in the posterior tissue. No probe was
common to both arrays. Each set of the 1,577 elements in-
cluded 10 positive and five negative rabbit controls. The re-
maining elements were Agilent probes for scanner alignment
and evaluating dye bias.
Glaucoma filtration surgery:  Six eight- to nine-week-
old male New Zealand white rabbits were obtained from
Charles River Laboratories (Wilmington, MA). Animals were
treated according to the ARVO Statement for the Use of Ani-
mals in Ophthalmic and Vision Research and in compliance
with institutional animal use and care guidelines. GFS was
performed using guidelines described in reference [8]. Briefly,
the eyelids were retracted using an eyelid speculum. A partial
thickness, corneal traction suture was placed in the superior
cornea and used to rotate the eye inferiorly. A limbus-based
conjunctival flap was fashioned in the superior lateral quad-
rant of the eye, approximately 8 mm from the limbus. The
conjunctiva and Tenon’s capsule were undermined by blunt
dissection until the limbus was reached. A clear corneal para-
centesis tract was made between the 5 and 7 o’clock positions
using a Beaver blade (Becton Dickinson & Co., Franklin Lakes,
NJ) and a viscoelastic material (Healon® 10 mg/ml, Pharmacia
& Upjohn) was injected to maintain the anterior chamber.
Starting close to the limbus, a needle tract tunnel was cre-
ated through the sclera and into the anterior chamber using a
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TABLE 1. PRIMER AND TAQMAN® PROBE SEQUENCES FOR SELECTED RABBIT GENES
       Gene                Forward primer                 TaqMan probe                  Reverse primer
-------------------   -------------------------   -------------------------------   ------------------------
Matrix
metalloproteinase-9   CCGGCATTCAGGGAGATG          CTGGGCAAGGGCGTCGTGGTT             TCGGCGTTTCCAAAGTACGT
Interleukin-1 beta    TTGCTGAGCCAGCCTCTCTT        CTGCCATTCAGGCAAGGCCAGC            CTGGGTACCAAGGTTCTTTGAACT
Transforming growth
factor beta-2         CGCCAAGGAGGTCTACAAGATAG     CATGCCGTCCTACTTCCCCTCCGA          GGTGGGTGGGATGGCATT
Transforming growth
factor beta-1         AAGGGCTACCACGCCAACT         AGTACAGCAAGGTCCTGGCCCTG(7Gs7Cs)   CCGGGTTGTGCTGGTTGT
Fibronectin           GTGGAATACGTGGTCAGTGTCTATG   CCGTTCCGGTTTTGTG                  TGGTGGTTACTGCAGTCTGAAC
Nucleotide sequence of the TaqMan® probe and both forward and reverse primers used in real-time PCR reactions. The probe and primer
sequences used in real-time PCR reactions and the microarray probe for individual rabbit genes were designed from the same contig.
165beveled 22G, IV cannula (Insyte®; Becton Dickinson Vascu-
lar Access, Sandy, UT). To reduce the risk of later iris ob-
struction the cannula was positioned so that its orifice was
beyond the pupillary margin, following withdrawal of the metal
cannula stylus. The distal end of the cannula was then trun-
cated so that its extrascleral portion was about 1mm in length.
The cannula was then tethered to the sclera, to prevent
dislodgement, with a single, encircling 10-0 nylon suture
(Ethicon Inc., Somerville, NJ). The conjunctiva and Tenon’s
capsule were finally closed in separate layers, in a watertight
fashion, using an 8-0 polygalactan (Vicryl®; Ethicon Inc.)
attached to a BV needle and a combined neomycin and dex-
amethasone ointment instilled into the cul-de-sac.
RNA isolation and target labeling:  Rabbits were sacri-
ficed 14 days after surgery. An approximate 4x4 mm section
of bleb tissue, consisting of conjunctiva and Tenon’s capsule
was harvested, immediately placed in a 1.5 mL microcentrifuge
tube, snap frozen in liquid nitrogen, and stored at -80 °C. Con-
junctiva and Tenon’s capsule tissue from the control eye was
harvested, frozen, and stored in the same manner.
Total RNA was extracted from tissue with an RNeasy®
Mini column (Qiagen, Valencia, CA). The quality of each
sample was evaluated from a 200 ng aliquot with a 2100
Bioanalyzer (Agilent Technologies). Quality was assessed
based on the relative abundance of the 18 and 28s ribosomal
bands and on the presence of baseline rise, both of which re-
vealed no RNA degradation. A 400 ng aliquot of total RNA
was used as template for complementary DNA (cDNA) syn-
thesis with the Low RNA Input Fluorescent Linear Amplifi-
cation Kit (Agilent Technologies) according to the manufac-
tures protocol. The subsequent cDNA product served as a tem-
plate for in vitro transcription (IVT), during which one of two
cyanine-labeled nucleotides (Perkin Elmer, Wellesley, MA)
was incorporated into the synthesized cRNA. All RNA samples
from the control eyes were labeled with cyanine 3-CTP (Cy3)
while bleb samples were labeled with cyanine 5-CTP (Cy5).
IVT reactions were cleaned with RNeasy® Mini columns
(Qiagen), and both cRNA concentration and specific activity
were measured with a ND-1000 spectrophotometer (NanoDrop
Technologies Wilmington, Delaware). The quality of each
cRNA sample was evaluated from a 200 ng aliquot with a
2100 Bioanalyzer (Agilent Technologies). Quality was as-
sessed by total yield, specific activity of product, and by the
presence of a smooth, mRNA-shaped curve of an appropriate
range in fragment size.
Array hybridization and generation of expression values:
Labeled cRNA samples were processed by the University of
Florida’s Interdisciplinary Center for Biotechnology Research
(ICBR) Gene Expression Core Facility (Gainesville, FL). For
each rabbit a 100 ng aliquot of the Cy5-labeled sample was
combined with a 100 ng aliquot from its paired Cy3-labeled
control. This mixture was incubated at 60 °C for 30 min in a
high salt buffer to fragment the labeled cRNA into 30-200
base strands. Arrays were hybridized at 60 °C for 17 h in a
rotating oven. After hybridization, arrays passed through both
a low and high stringency wash according to the manufacture’s
protocols. Arrays were dried with filtered nitrogen gas and
scanned in each of two wavelengths (green: 570, red: 670)
with an Agilent G2505 B Scanner (Agilent Technologies).
Signal values were corrected for both local background and
potential differences in hybridization intensity across the ar-
ray. A red:green signal ratio was calculated for each element,
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Figure 1. Examples of images gen-
erated from scanned microarrays.
Example of an image generated
from a scanned eight-pack
microarray (A) and a single 1,900
element (B) microarray. Each circle
represents a unique spotted probe.
Red probes indicate that gene ex-
pression in the surgically treated eye
is higher than in the control, while
green marks higher gene expression
in the control. Yellow indicates no
difference in gene expression be-
tween the surgically treated and
control eyes. Black denotes absence
of detectable signal.
166and ratios were normalized with a lowess transformation. All
corrections and transformations of signal values were per-
formed with Feature Extraction software version 8.1 (Agilent
Technologies).
A one-group Student’s t-test was performed on log2 trans-
formed signal ratios of each probe individually. The null hy-
pothesis, that surgery does not affect probe transcript level,
was rejected if the ratio were significantly different from zero.
Statistical tests were performed with AnalyzeIt Tools software
developed by ICBR.
Real-time polymerase chain reaction:  Quantitative real-
time polymerase chain reaction (PCR) was performed on bleb
and control RNA samples for five rabbit genes: interleukin 1-
β (IL1β), matrix metalloproteinase-9 (MMP9), transforming
growth factor-β1 (TGFβ1), transforming growth factor-β2
(TGFβ2) and fibronectin (FN1). Real-time PCR was simulta-
neously performed for 18s ribosomal RNA, and its expres-
sion served as an internal control. All primers and TaqMan®
probes were designed and synthesized by Applied Biosystem
(Foster City, CA; Table 1). Reverse transcription was primed
with random hexamers. Real-time reactions were performed
in a 25 µl volume containing a 1X solution of TaqMan® Uni-
versal PCR Master Mix, 200 nM of forward primer, 200 nM
of reverse primer, 50 nM of probe, and 20 ng of template
cDNA. The reaction was initially heated to 50 °C for 2 min,
then the temperature was raised to 95 °C for 10 min, and fol-
lowed by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. All
real-time reactions were performed with the 7900HT sequence
detection system (Applied Biosystems, Foster City, CA). Both
bleb and control samples were assayed in triplicate. Relative
quantitative of expression levels was determined for each gene.
All results are expressed as an expression ratio of the bleb to
control tissue, normalized against 18s expression levels.
RESULTS
Sequencing:  For each library, 3,840 clones were sequenced
from both 5' and 3' ends. After removal of empty vector, E.coli
and mitochondrial contaminants, high quality sequences were
obtained for 3,118 and 3,418 clones from the anterior tissue
library (library identifier: naf) and posterior tissue library (li-
brary identifier: nag), respectively. The average quality read
length was 599 bases for naf and 626 bases for nag. After
GRIST analysis, the naf data yielded 1,929 potentially unique
gene clusters, while nag produced 1870 clusters. Annotated
sequence information is available at the NEIBank rabbit li-
brary website. In addition, names and annotation of microarray
probes for all contigs and those represented on each microarray
can be found at the University of Florida Ophthalmic Gene
Microarray Project.
Treatment effects:  An example of a scanned slide is shown
in Figure 1. Of the 3,154 total probes present on the two ar-
rays, 2,522 had a signal value above the background, in either
the red or green channel, on at least two experimental arrays.
Genes represented by these probes were considered present.
The remainder were considered absent (no expression under
any experimental condition). However, some of the absent calls
may be attributed to “bad” probes which have suboptimal hy-
bridization characteristics and may not work under any ex-
perimental conditions. Only future hybridizations under dif-
ferent experimental conditions will allow us to determine
which probes need to be redesigned.
A one-group Student’s t-test was performed on log2 trans-
formed signal ratios (red versus green) to identify genes whose
expression was significantly effected by GFS. The null hy-
pothesis was rejected if the ratio was significantly different
form zero. The expression of 71 and 315 (Table 2) genes was
significantly altered by GFS at the p=0.01 and 0.05 level, re-
spectively. The expression of 26 genes changed by more than
two-fold and the expression of five by more than four-fold
(Table 3). Of the 26 genes that changed by more than two
fold, only 16 had an assigned GO annotation for biological
process (Table 3). The biological process connected with all
but two of these genes is characteristic of those associated
with tissue injury and healing.
Real-time polymerase chain reaction:  Sufficient quanti-
ties of RNA were only available to perform real-time PCR on
four of the six original rabbit ocular samples. The changes in
expression level of IL1B, MMP9, TGFB1, TGFB2, and FN1
are listed in Table 4. Of these five genes, the expression of
two, IL1B and MMP9, increased dramatically (>100 fold). The
expression of two, FN1 and TGFB1, increased moderately
(three- to six-fold) and the expression of one, TGFB2, was
unchanged. The array-based expression changes in IL1B,
MMP9, and FN1 were generally consistent with those of real-
time PCR in that the expression of both IL1B and MMP9 in-
creased significantly and dramatically. For example, of the
3,155 genes present on the array, IL1B and MMP9 had the
second and fifth largest change in gene expression, respec-
tively. Additionally, the expression of FN1 increased signifi-
cantly, but to a lesser degree than IL1B and MMP9.
Real-time results for TGFB1 and TGFB2 were more dif-
ficult to interpret. For TGFB2, the signal values in the green
channel were inordinately high. Only on the fourth array, where
there was a small increase in the red signal, were the real-time
and array results consistent. For TGFB1, the results were dif-
ficult to interpret because all the signal values were close to
background levels. On two of the arrays, gene expression goes
from present to absent, but the remaining two, gene expres-
sion goes from absent to present. Therefore, an accurate esti-
mate of fold change was not possible.
DISCUSSION
 Rabbits, because of their large eyes, ease of handling, and
cost effectiveness of their use, have become an important and
standard ophthalmic animal model for many surgical experi-
ments as well as for the development of new devices and medi-
cal therapies. To date, the research community has been forced
to use commercially available chips for similar model sys-
tems (rat) due to the absence of rabbit arrays. When this project
was initiated, only a small amount of rabbit sequence was avail-
able from which microarray probes could be designed. To this
end, we have successfully sequenced cDNA inserts from clones
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TABLE 2. ALTERED GENE EXPRESSION FOLLOWING GLAUCOMA
FILTRATION SURGERY
                          Mean log2
 Probe name     p value   difference                Hit definition                E-value
-------------   -------   ----------   ----------------------------------------   -------
UF_Oc_c_40007    0.001      -0.44      13kDa differentiation-associated protein     0.0
UF_Mm_31359      0.023       0.49      2310004I24Rik protein                        0.0
UF_Mm_31415      0.022       0.79      2810480G15Rik protein                        0.0
UF_Oc_r_30841    0.002       0.36      2-aminomuconic acid semialdehyde             0.9
                                         dehydrogenase
UF_Oc_c_40335    0.037      -0.64      3-methyl-2-oxobutanoate dehydrogenase        0.0
UF_Oc_n_41433    0.027       0.51      5-HT3 receptor                               0.0
UF_Oc_c_40101    0.044      -0.52      Acetyl-CoA acetyltransferase                 0.0
UF_Mm_31324      0.017       0.59      Acid sphingomyelinase-like                   0.0
                                         phosphodiesterase 3a
UF_Oc_c_40551    0.023       0.33      Adipose differentiation-related protein;     0.0
                                         adipophilin
UF_Oc_n_41499    0.008      -0.45      ADP/ATP translocase                          0.0
UF_Oc_r_30414    0.022      -0.51      ADP-ribosylation factor-like 6               0.0
UF_Oc_n_41261    0.034       0.30      Aggrecan core protein                        0.0
UF_Oc_n_31524    0.005       0.67      Aggrecanase-2                                0.0
UF_Oc_r_30810    0.037       0.14      AgrB                                         0.7
UF_Oc_n_41308    0.020       2.81      Alpha-1-acid glycoprotein                    0.0
UF_Oc_c_40520    0.044       0.77      Alpha-1-glycoprotein                         0.0
UF_Oc_r_30067    0.004      -1.52      Alpha-actinin-2-associated LIM protein       0.0
UF_Oc_c_40392    0.011       0.92      Anterior gradient 2 homolog                  0.0
UF_Oc_c_40535    0.045       0.21      Apolipoprotein D                             0.0
UF_Oc_r_30343    0.033      -0.38      ATP synthase, H+ transporting,               0.0
                                         mitochondrial F1 complex, beta
                                         polypeptide
UF_Oc_r_30203    0.048       0.22      BAP31                                        0.0
UF_Oc_n_41216    0.007       0.93      Beta casein                                  0.0
UF_Oc_n_41423    0.010      -0.87      Beta tropomyosin                             0.0
UF_Oc_n_41440    0.032       0.57      Beta-arrestin 1                              0.0
UF_Oc_r_31084    0.048       0.31      Bifunctional cbiH protein and                5.0
                                         precorrin-3B C17-methyltransferase
UF_Oc_c_40296    0.012      -0.12      BMS1-like, ribosome assembly protein         0.0
UF_Oc_c_40651    0.040       0.44      Bromo-adjacent homology                      0.5
                                         domain-containing protein
UF_Oc_r_31039    0.011      -0.76      C. elegans SRA-13 protein                    3.9
UF_Oc_c_40046    0.018      -0.69      Ca2+-transporting ATPase                     0.0
UF_Oc_m_40223    0.012      -0.36      Calmodulin 1 (phosphorylase                  0.0
                                         kinase, delta)
UF_Oc_r_30531    0.003       1.11      Cathepsin B                                  0.0
UF_Oc_n_41428    0.020       1.05      Cathepsin E                                  0.0
UF_Oc_c_40013    0.000       2.07      Cathepsin K                                  0.0
UF_Oc_n_41131    0.030       0.49      CD36 antigen                                 0.0
UF_Oc_r_31102    0.035      -0.87      Cell cycle control protein                   6.0
UF_Oc_c_41026    0.032       0.48      CG11023-PA                                   7.4
UF_Oc_c_40760    0.024      -0.38      CG6137-PA                                    1.7
UF_Oc_m_30175    0.013      -0.29      Chaperonin containing TCP1,                  0.0
                                         subunit 2 (beta)
UF_Oc_m_40241    0.048      -0.29      Chaperonin containing TCP1,                  0.0
                                         subunit 2 (beta)
UF_Oc_c_40835    0.029      -0.35      Chloroquine resistance marker                2.8
                                         protein, putative
UF_Oc_n_41489    0.008      -2.06      Chondromodulin-I                             0.0
UF_Oc_y_31574    0.040       0.38      Chromosome 17 open reading frame 37          0.0
UF_Oc_r_30335    0.003       0.52      Complement C4A                               0.0
UF_Oc_r_30932    0.018       0.74      Conserved hypothetical protein               1.9
UF_Oc_c_40995    0.013       0.35      Conserved hypothetical protein               6.5
UF_Oc_c_40346    0.040      -1.25      Corneal endothelium specific protein 1       0.0
UF_Oc_c_40478    0.024      -1.66      Corneal endothelium specific protein 1      0.0
UF_Oc_r_30192    0.014      -0.72      CRTAC1-B protein                             0.0
UF_Mm_31242      0.027       0.67      Cryptochrome 1                               0.0
UF_Oc_n_41539    0.009       1.04      Cystatin B                                   0.0
UF_Oc_n_41097    0.006       0.47      Cystic fibrosis transmembrane                0.0
                                         conductance regulator
UF_Oc_m_40228    0.045       0.25      Cytochrome b                                 0.0
UF_Oc_r_30452    0.011      -0.32      Cytochrome c oxidase subunit I               0.0
UF_Oc_r_30490    0.003       0.47      Cytochrome c oxidase subunit III             0.0
UF_Oc_n_41352    0.020      -1.35      Cytochrome P450 2A10                         0.0
UF_Oc_n_41474    0.024       0.15      Cytochrome P450 8B1                          0.0
UF_Oc_r_30439    0.016       0.40      Cytoskeleton-associated protein 1            0.0
UF_Oc_c_40165    0.040      -0.56      DEAD (Asp-Glu-Ala-Asp) box polypeptide 1     0.0
UF_Oc_c_40175    0.004      -0.79      Dihydrolipoamide dehydrogenase               0.0
UF_Oc_r_30308    0.028      -0.72      Dimeric dihydrodiol dehydrogenase            0.0
UF_Oc_r_30024    0.036      -0.46      DKFZP564B167 protein                         0.0
UF_Mm_31202      0.004      -0.91      DNA segment, Chr 6, ERATO Doi 253            0.0
UF_Oc_r_30647    0.030       0.33      DNA topoisomerase, type I                    0.1
UF_Oc_r_30660    0.039       0.43      DNA-directed RNA polymerase II               0.1
                                         largest subunit
UF_Oc_r_30059    0.025      -0.40      DnaJ homolog, subfamily A, member 2          0.0
UF_Oc_r_30305    0.042      -0.23      DSIF p160                                    0.0
UF_Oc_r_30277    0.002      -0.49      Dynactin 1                                   0.0
UF_Oc_m_30346    0.019      -0.82      ENO1 protein                                 0.0
UF_Oc_r_30721    0.022       0.10      ENSANGP00000019839                           0.3
UF_Oc_r_30587    0.016      -0.68      EPAS1 protein                                0.0
UF_Oc_c_40498    0.011       0.92      Epithelial chloride channel protein          0.0
UF_Oc_r_30788    0.037      -0.32      Eukaryotic translation initiation            0.5
                                         factor 2B
UF_Oc_r_31113    0.022      -0.62      Eukaryotic translation initiation            6.4
                                         factor 5
UF_Oc_y_41571    0.006       0.32      EWS/ZSG fusion protein short isoform         0.0
UF_Oc_r_30768    0.014       0.73      Expressed sequence AI462446                  0.4
UF_Oc_r_30758    0.028      -0.36      Fibrillar collagen                           0.4
UF_Oc_n_31501    0.011       1.28      Fibronectin                                  0.0
UF_Oc_n_41550    0.002      -0.59      FK506-binding protein 3                      0.0
UF_Oc_r_30610    0.017       0.33      Foocen-m2                                    0.0
UF_Oc_r_30129    0.011      -0.62      FUS/TLS protein                              0.0
UF_Oc_r_30813    0.035       0.68      GABA/noradrenaline transporter               0.7
UF_Oc_c_40112    0.050      -0.50      GL004 protein                                0.0
UF_Oc_r_30658    0.050      -0.20      GL014                                        0.1
UF_Oc_c_40973    0.035      -0.78      GLP_680_59866_66603                          6.0
UF_Oc_c_40723    0.032       0.97      GLP_82_33920_36064                           1.3
UF_Oc_n_31557    0.016       0.77      Glucocorticoid receptor                      0.0
UF_Oc_m_30398    0.008      -0.62      Glucocorticoid-induced leucine zipper        0.0
UF_Oc_m_40359    0.016      -0.69      Glucocorticoid-induced leucine zipper        0.0
UF_Mm_31290      0.011       0.27      Glutamine fructose-6-phosphate               0.0
                                         transaminase 1
UF_Oc_n_41492    0.033      -0.79      Glyceraldehyde 3-phosphate dehydrogenase     0.0
UF_Oc_n_41246    0.002      -0.80      Glyceraldehyde 3-phosphate dehydrogenase     0.0
UF_Oc_n_41208    0.006      -0.71      Glycogen debranching enzyme                  0.0
UF_Oc_n_41424    0.037       0.25      GPI-linked NAD(P+)--arginine                 0.0
                                         ADP-ribosyltransferase 1
UF_Oc_c_40796    0.047       0.39      Gro-1 Operon gene GOP-1, GOP-1               2.2
UF_Oc_n_41431    0.016       0.34      GTPase regulator associated with the         0.0
                                         focal adhesion kinase pp125
UF_Oc_c_40925    0.019       0.22      Heat shock protein 17.8                      4.8
UF_Oc_n_41231    0.050       0.25      Heat shock protein 8                         0.0
UF_Oc_c_40953    0.032       0.19      Heme maturase                                5.5
UF_Mm_31240      0.022       0.47      Heparan sulfate glucosaminyl                 0.0
                                         N-deacetylase/N-sulfotransferase
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UF_Oc_c_40160    0.000      -0.46      Heterogeneous nuclear                        0.0
                                         ribonucleoprotein C
UF_Oc_n_41472    0.023       0.21      Histocompatibility antigen DM                0.0
                                         Heterodimer heavy chain
UF_Oc_r_30332    0.016      -0.64      HRMT1L2 protein                              0.0
UF_Oc_r_30569    0.018       0.33      Hypothetical class II basic                  0.0
                                         helix-loop-helix protein
UF_Oc_r_30551    0.037       0.74      Hypothetical protein                         0.0
UF_Oc_r_30950    0.012       0.69      Hypothetical protein                         2.2
UF_Oc_c_40650    0.031       0.65      Hypothetical protein                         0.5
UF_Oc_c_40582    0.037       0.49      Hypothetical protein                         0.1
UF_Oc_c_40929    0.014       0.49      Hypothetical protein                         4.9
UF_Oc_r_30852    0.034       0.42      Hypothetical protein                         1.0
UF_Oc_r_31105    0.045       0.38      Hypothetical protein                         6.1
UF_Oc_c_40704    0.028       0.25      Hypothetical protein                         1.1
UF_Oc_c_40776    0.020       0.24      Hypothetical protein                         1.8
UF_Oc_c_41030    0.042      -0.15      Hypothetical protein                         7.4
UF_Oc_r_30710    0.049      -0.22      Hypothetical protein                         0.2
UF_Oc_c_40581    0.043      -0.37      Hypothetical protein                         0.1
UF_Oc_r_30692    0.019      -0.47      Hypothetical protein                         0.2
UF_Oc_c_40956    0.006      -0.73      Hypothetical protein                         5.6
UF_Oc_c_40928    0.001      -0.75      Hypothetical protein                         4.8
UF_Oc_r_30565    0.006      -1.70      Hypothetical protein                         0.0
UF_Oc_r_30056    0.043      -0.63      Hypothetical protein BC009732                0.0
UF_Oc_c_41054    0.043       0.45      Hypothetical protein Cj0447                  8.0
UF_Oc_r_30796    0.042       0.32      Hypothetical protein Daro140001              0.6
UF_Oc_r_31033    0.005       0.91      Hypothetical protein Daro170901              3.8
UF_Oc_r_30050    0.031       0.52      Hypothetical protein DKFZp761A052.1          0.0
UF_Oc_c_40882    0.025       0.68      Hypothetical protein DKFZp761H221.1          3.5
UF_Oc_r_31126    0.034       0.16      Hypothetical protein Exigu022705             7.3
UF_Oc_c_40979    0.047       0.27      Hypothetical protein FG08398.1               6.2
UF_Oc_c_40111    0.013       0.44      Hypothetical protein MGC14353;               0.0
                                         thioredoxin (Trx)-related
                                         protein, 14 kDa
UF_Oc_y_31570    0.022      -0.31      Hypothetical protein MGC33212                0.0
UF_Oc_c_40023    0.019      -0.45      Hypothetical protein MGC4825                 0.0
UF_Oc_c_40649    0.024      -0.32      Hypothetical protein OB1070                  0.5
UF_Mm_31461      0.018       0.42      Hypothetical protein RL076                   0.6
UF_Oc_r_30623    0.048       0.32      Hypothetical protein UL126                   0.0
UF_Oc_c_40933    0.031       0.29      Hypothetical protein UM01639.1               5.0
UF_Oc_c_40842    0.018       0.42      Hypothetical protein UM01797.1               2.9
UF_Oc_n_41124    0.041      -0.44      Hypoxanthine phosphoribosyltransferase       0.0
UF_Oc_n_41230    0.048      -0.77      Hypoxia inducible factor 1 alpha subunit     0.0
UF_Mm_31343      0.012       0.42      Hypoxia up-regulated 1; calcium binding      0.0
                                         protein, 140 kDa
UF_Oc_n_41458    0.016       0.30      Immunoglobulin heavy chain                   0.0
                                         variable region
UF_Oc_n_41415    0.041       0.41      Immunoglobulin heavy chain VDJ region        0.0
UF_Oc_n_31509    0.046      -0.35      Importin beta-3                              0.0
UF_Oc_c_40458    0.017      -0.29      Inositol(myo)-1(or 4)-monophosphatase 1      0.0
UF_Oc_n_31512    0.029       0.59      Integrin beta1                               0.0
UF_Oc_n_41542    0.006       0.18      Interleukin 6                                0.0
UF_Oc_n_41565    0.007       3.11      Interleukin-1 beta                           0.0
UF_Oc_r_30860    0.008       0.40      Iron (III) ABC transporter,                  1.1
                                         ATPase component
UF_Mm_31347      0.033       0.20      Junction adhesion molecule 3                 0.0
UF_Mm_31262      0.006       0.30      Karyopherin alpha 2                          0.0
UF_Oc_r_30101    0.016       0.38      KIAA0077                                     0.0
UF_Oc_r_30624    0.044      -0.58      KIAA0653 protein                             0.0
UF_Oc_r_30281    0.048       0.25      KIAA0735 protein                             0.0
UF_Oc_c_40209    0.001      -0.37      KIAA1289 protein                             0.0
UF_Oc_n_41561    0.045      -0.10      Lactase-glycosylceramidase                   0.0
UF_Mm_31425      0.011       0.41      Lanosterol synthase                          0.0
UF_Oc_c_40685    0.018      -0.56      LD11664p                                     0.8
UF_Oc_n_41277    0.007       0.60      Low density lipoprotein-related              0.0
                                         protein 1
UF_Oc_c_40419    0.042       1.37      Lumican                                      0.0
UF_Oc_c_40213    0.048       1.05      Lumican                                      0.0
UF_Oc_c_40194    0.010       1.32      LysozymeC(1,4-beta-N-acetylmuramidase C)     0.0
UF_Oc_r_30224    0.035       0.45      Lysyl oxidase-like protein                   0.0
UF_Oc_r_31041    0.034       0.23      Macrolide-efflux protein                     3.9
UF_Oc_c_40724    0.041       0.19      MADS box protein TDR4                        1.3
UF_Oc_c_40715    0.038       1.17      Major facilitator family transporter         1.2
UF_Oc_m_40252    0.022       0.25      Mammary tumor integration site 6             0.0
                                         oncogene protein
UF_Oc_n_41311    0.021       0.20      MAPK-activated protein kinase 2              0.0
UF_Oc_n_41197    0.018       0.58      Matrix metalloproteinase-1                   0.0
UF_Oc_n_41283    0.008       1.85      Matrix metalloproteinase-9                   0.0
UF_Oc_c_40923    0.009      -0.35      Maturase                                     4.7
UF_Oc_r_30559    0.014       0.24      Membrane protein TGN38 long form             0.0
UF_Oc_n_31527    0.019       0.80      MGC5309 protein                              0.0
UF_Oc_c_40323    0.020       0.87      MHC class II histocompatibility antigen      0.0
                                         RLA-DQ alpha chain
UF_Oc_c_40271    0.005      -0.50      Mitochondrial ATP synthase, O subunit        0.0
UF_Oc_c_40449    0.021       0.16      Mitochondrial isoleucine tRNA synthetase     0.0
UF_Oc_n_41237    0.006      -1.06      Mono (ADP-ribosyl)transferase                0.0
UF_Oc_n_41350    0.024       0.32      Monocyte differentiation antigen CD14        0.0
UF_Oc_c_40183    0.041      -0.33      Multi-PDZ-domain-containing protein          0.0
UF_Oc_c_40471    0.041       0.78      Mutant alpha-1 collagen type 1               0.0
UF_Oc_c_40493    0.008       0.31      NADH dehydrogenase subunit 3                 0.0
UF_Oc_c_40622    0.010      -1.00      NADH dehydrogenase subunit 4                 0.3
UF_Mm_31429      0.050      -0.22      NADH dehydrogenase, Fe-S protein 2           0.0
UF_Oc_c_40140    0.004      -0.29      NADH dehydrogenase, Fe-S protein 4           0.0
UF_Oc_c_40409    0.019      -0.70      NADH dehydrogenase1 alpha subcomplex 4       0.0
UF_Oc_n_31543    0.033       0.45      NADP(H)-oxidase                              0.0
UF_Mm_31371      0.014       0.14      Nedd4 WW binding protein 4                   0.0
UF_Oc_c_40416    0.002       1.83      Neutrophil granules matrix glycoprotein      0.0
UF_Oc_r_30451    0.021       0.32      NIR2                                         0.0
UF_Oc_n_41335    0.041       0.23      Nitric oxide synthase, inducible             0.0
UF_Oc_r_30229    0.037      -0.55      N-myc downstream-regulated                   0.0
                                         gene 2 isoform b
UF_Oc_r_30979    0.050       0.40      Non-phototropic hypocotyl 3                  2.7
UF_Oc_n_31505    0.013       0.27      Nuclear receptor subfamily 5 group A         0.0
                                         member 2
UF_Mm_31360      0.032       0.70      Nudix (nucleoside diphosphate linked         0.0
                                         moiety X)-type motif 2
UF_Oc_r_30432    0.046       0.26      OK/SW-CL.33                                  0.0
UF_Hs_31471      0.011       0.62      Optineurin                                   0.0
UF_Oc_n_41275    0.038      -0.26      ORM1-like 2                                  0.0
UF_Oc_c_40096    0.020       0.08      Peptidyl prolyl isomerase H                  0.0
UF_Oc_r_30217    0.013      -0.47      Peptidyl-prolyl cis/trans isomerase          0.0
UF_Mm_31468      0.006       0.35      Permeases of the drug/metabolite             3.9
                                         transporter superfamily
UF_Oc_n_41377    0.023      -0.76      Phosphatidylethanolamine-binding protein     0.0
UF_Oc_m_30183    0.043      -0.48      Phosphoglycerate kinase 1                    0.0
UF_Oc_n_41437    0.030       0.16      Phospholipase A2                             0.0
UF_Oc_n_41418    0.018       0.35      Potassium inwardly-rectifying channelJ10     0.0
UF_Oc_m_31072    0.021      -0.53      Prespore-specific protein                    4.7
UF_Mm_31207      0.021       0.17      Procollagen, type VI, alpha 3                0.0
UF_Oc_c_40554    0.022       0.40      Proline-rich protein                         0.0
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UF_Oc_r_30983    0.034       0.30      Prolyl endopeptidase                         2.8
UF_Oc_r_30326    0.016      -0.21      Proteasome 26S subunit, non-ATPase, 3        0.0
UF_Mm_31331      0.003       0.63      Protein inhibitor of activated               0.0
                                         STAT PIASy
UF_Mm_31303      0.038      -0.56      Protein phosphatase 1D                       0.0
                                         magnesium-dependent, delta isoform
UF_Oc_c_40192    0.041      -0.40      Protein phosphatase 2, catalytic             0.0
                                         subunit, alpha isoform
UF_Oc_c_40376    0.002       0.37      Protein transport protein                    0.0
                                         SEC61 beta subunit
UF_Oc_r_30690    0.048       0.31      Putative gamma-glutamyltranspeptidase        0.2
UF_Oc_c_40531    0.028       0.72      Putative nuclear protein (1H963)             0.0
UF_Oc_c_40972    0.047      -0.17      Putative signal transducer                   6.0
UF_Oc_c_40587    0.011       0.61      Putative yir4 protein                        0.1
UF_Oc_c_40146    0.014      -0.56      Pyruvate dehydrogenase E1 component          0.0
                                         beta subunit
UF_Oc_r_30286    0.030      -0.40      Pyruvate kinase, M1 isozyme                  0.0
UF_Mm_31406      0.007       0.15      Quininoid dihydropteridine reductase         0.0
UF_Oc_r_30365    0.029       0.32      RAB5-interacting protein isoform a           0.0
UF_Oc_c_40043    0.002       0.21      Ribosomal protein L27                        0.0
UF_Oc_c_40300    0.042       0.37      Ribosomal protein L31; 60S ribosomal         0.0
                                         protein L31
UF_Oc_c_40110    0.038       0.70      Ribosomal protein L5                         0.0
UF_Oc_m_30176    0.030       0.39      Ribosomal protein S12                        0.0
UF_Oc_c_40373    0.014       0.31      Ribosomal protein S26                        0.0
UF_Oc_m_40235    0.003      -0.34      Ribosomal protein S3a; 40S ribosomal         0.0
                                         protein S3a
UF_Mm_31352      0.011       0.91      Ribosome binding protein 1                   0.0
                                         isoform mRRp61
UF_Oc_c_40391    0.040      -0.33      RIKEN cDNA 1110020P15                        0.0
UF_Mm_31177      0.010       0.39      RIKEN cDNA 1300017E09                        0.0
UF_Mm_31399      0.017       0.75      RIKEN cDNA 2510025F08                        0.0
UF_Mm_31403      0.041       0.16      RIKEN cDNA 4930556P03                        0.0
UF_Oc_r_30988    0.039       0.66      RIKEN cDNA 4933437K13                        2.9
UF_Oc_r_30495    0.007      -0.76      RIKEN cDNA A530046H20                        0.0
UF_Oc_c_40331    0.004      -0.27      Ring-box 1                                   0.0
UF_Oc_r_30892    0.005      -0.54      RNA polymerase beta chain                    1.5
UF_Oc_c_40403    0.050       0.19      SECP43 protein                               0.0
UF_Mm_31341      0.008       0.37      Secreted modular calcium-binding             0.0
                                         protein 2
UF_Oc_r_30486    0.006       0.38      Seipin                                       0.0
UF_Oc_n_41531    0.016       1.20      Serum amyloid A-1                            0.0
UF_Oc_n_41285    0.001       4.48      Serum amyloid A-3 protein                    0.0
UF_Oc_c_40486    0.048       0.36      Similar to 40S ribosomal protein S6          0.0
UF_Oc_c_40398    0.021       0.31      Similar to 60S ribosomal protein L34         0.0
UF_Oc_r_30580    0.028       0.20      Similar to Ac2-210                           0.0
UF_Oc_r_30431    0.041      -0.48      Similar to CG5987-PA                         0.0
UF_Oc_n_41235    0.012      -0.57      Similar to cyclin I                          0.0
UF_Mm_31214      0.044       0.60      Similar to ganglioside-induced               0.0
                                         differentiation associated protein 3
UF_Oc_r_30968    0.001       0.28      Similar to hypothetical protein              2.5
UF_Oc_c_40524    0.040      -0.59      Similar to hypothetical                      0.0
                                         protein 9630041N07
UF_Oc_r_30389    0.012       1.87      Similar to Ldb1a                             0.0
UF_Mm_31272      0.038       0.22      Similar to NNX3                              0.0
UF_Oc_n_41147    0.008       0.53      Similar to Nucleolar RNA helicase II         0.0
UF_Oc_c_40138    0.044       0.20      Similar to ribosomal protein L30             0.0
UF_Oc_r_30322    0.036      -0.29      Similar to RIKEN cDNA 0610043B10             0.0
UF_Mm_31394      0.034      -0.11      Similar to RIKEN cDNA 5730403E06             0.0
UF_Oc_c_40614    0.038       0.70      Similar to T cell receptor V delta 8         0.3
UF_Oc_c_40202    0.006      -0.51      Similar to ubiquinol-cytochrome c            0.0
                                         reductase binding protein
UF_Oc_r_30007    0.039      -0.51      Single-stranded DNA binding protein 2        0.0
UF_Oc_n_41236    0.017      -0.33      SLC26A7                                      0.0
UF_Mm_31395      0.000       0.87      Sloan-Kettering viral oncogene homolog       0.0
UF_Oc_c_40348    0.030       0.33      Small nuclear ribonucleoprotein              0.0
                                         polypeptide E
UF_Mm_31313      0.022       0.68      SMC1 structural maintenance of               0.0
                                         chromosomes 1-like 1
UF_Oc_n_41221    0.014       0.44      Sodium/glucose cotransporter 1               0.0
UF_Oc_r_30466    0.030      -0.63      Sodium/potassium/calcium exchanger 3         0.0
UF_Oc_n_31523    0.002       0.44      Sperm-binding glycoprotein ZP2               0.0
UF_Mm_31221      0.001       0.35      Splicing factor, arginine/serine-rich 5      0.0
UF_Oc_n_41289    0.027      -0.59      Succinate dehydrogenase                      0.0
UF_Oc_c_40012    0.047      -0.31      SUMO-1 activating enzyme subunit 2           0.0
UF_Oc_c_40388    0.032      -0.57      Synovial sarcoma translocation gene on       0.0
                                         chromosome 18-like 2; kiaa-iso protein
UF_Oc_n_41132    0.049       0.28      T-cell receptor beta-chain precursor         0.0
UF_Mm_31311      0.035       0.49      Telomerase binding protein, p23              0.0
UF_Oc_c_41090    0.038       0.59      Thymosin, beta 4, X chromosome;              0.0
                                         prothymosin beta 4
UF_Oc_n_41317    0.014       0.89      Tissue inhibitor of metalloproteinase-2      0.0
UF_Oc_c_41076    0.048       0.59      Transcriptional regulator                    9.0
UF_Oc_n_31168    0.016       0.17      Transforming growth factor alpha             0.0
UF_Oc_n_41523    0.020      -0.29      Translation initiation factor                0.0
                                         eIF-2B-delta
UF_Oc_c_40042    0.001       0.26      Translokin                                   0.0
UF_Oc_r_30842    0.002       0.40      Tryptophanyl-tRNA synthetase                 0.9
UF_Oc_c_40794    0.035      -0.46      Tubulin beta chain                           2.1
UF_Mm_31328      0.020       0.79      Tweety homolog 1                             0.0
UF_Oc_r_30020    0.006      -0.70      Ubiquinol-cytochrome c reductase,            0.0
                                         Rieske iron-sulfur polypeptide 1
UF_Mm_31210      0.019       0.66      Ubiquitin ligase E3 alpha-II                 0.0
UF_Oc_c_40115    0.032      -0.71      Uncharacterized hematopoietic                0.0
                                         stem/progenitor cells protein MDS029
UF_Oc_r_30772    0.003       0.76      Unknown                                      0.5
UF_Oc_r_31071    0.016       0.71      Unknown                                      4.6
UF_Oc_r_30995    0.023       0.50      Unknown                                      3.1
UF_Oc_r_30628    0.014       0.44      Unknown                                      0.0
UF_Oc_c_41047    0.004       0.40      Unknown                                      7.8
UF_Oc_c_40641    0.017       0.39      Unknown                                      0.5
UF_Oc_c_41089    0.034       0.30      Unknown                                      9.8
UF_Oc_m_41084    0.026       0.26      Unknown                                      9.4
UF_Oc_r_30901    0.037       0.18      Unknown                                      1.6
UF_Oc_r_30563    0.047       0.12      Unknown                                      0.0
UF_Oc_r_31141    0.024      -0.14      Unknown                                      8.0
UF_Oc_c_40874    0.004      -0.23      Unknown                                      3.4
UF_Oc_c_40868    0.005      -0.37      Unknown                                      3.3
UF_Oc_r_31012    0.023      -0.39      Unknown                                      3.5
UF_Oc_r_30622    0.044      -0.41      Unknown                                      0.0
UF_Oc_c_40813    0.044      -0.47      Unknown                                      2.5
UF_Oc_c_40821    0.024      -0.60      Unknown                                      2.6
UF_Oc_c_40282    0.032      -0.82      Unknown                                      0.0
UF_Oc_c_40775    0.048      -0.94      Unknown                                      1.8
UF_Oc_c_40341    0.045       0.35      Unnamed protein                              0.0
UF_Oc_c_40699    0.021       0.25      Unnamed protein                              1.0
UF_Oc_r_30370    0.020       0.20      Unnamed protein                              0.0
UF_Oc_c_40420    0.010      -0.45      Unnamed protein                              0.0
UF_Oc_m_40305    0.019      -0.50      Unnamed protein                              0.0
UF_Oc_m_30347    0.031      -0.61      Unnamed protein                              0.0
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UF_Oc_r_30055    0.032      -0.71      Unnamed protein                              0.0
UF_Oc_r_30237    0.042       0.56      Vacuolar ATP synthase 16 kDa                 0.0
                                         proteolipid subunit
UF_Oc_n_41218    0.033       0.22      Vacuolar proton-translocating ATPase a2      0.0
                                         isoform
UF_Oc_n_41254    0.023       0.28      Vascular endothelial growth factor           0.0
                                         receptor 3
UF_Oc_n_41151    0.008      -0.25      V-erb-a erythroblastic leukemia viral        0.0
                                         oncogene homolog 4
UF_Oc_n_41502    0.022      -1.05      Voltage-dependent anion channel 1            0.0
UF_Oc_r_30382    0.003       1.74      X-ray crystal structure of human             0.0
                                         ceruloplasmin at 3.0 Angstroms
UF_Oc_c_40769    0.050       0.42      Zn-dependent carboxypeptidase                1.8
UF_Oc_r_31024    0.027       0.49      Zonadhesin                                   3.6
Genes whose expression was significantly (p less than or equal to
0.05) altered by glaucoma filtration surgery. Mean log2 difference is
the level of gene expression in tissue surrounding the surgical site
compared to similar tissue from control eye. The p value represents
the level of significance in treatment means, the hit definition is the
name of the most homologous gene, and E-value is the level of con-
fidence that the matched name is incorrect.
originating from rabbit ocular tissues. These sequences are
available to the public. In addition, we developed two rabbit
arrays containing a total of 3,154 unique contigs.
To the best of our knowledge, this study represents the
first report using a rabbit microarray. Because so little rabbit
sequence was available prior to this study, it was difficult to
make direct comparisons with other rabbit studies, which have
focused only on the expression of one or a few genes. There-
fore, we compared our results with those from other model
systems. Because direct comparisons were made between spe-
cies and with nonhomologous, studies we compared the gen-
eral biological interpretation of results between studies.
In a generalized model of wound healing, initial tissue
injury stimulates various signaling events including the re-
lease of local cytokines and growth factors that eventually led
to the production of structural proteins that are components of
the extracellular matrix. To evaluate the biological validity of
our rabbit microarrays we compared the results with those of
our previous rat GFS study [9]. In our rat microarray study,
we examined changes in gene expression 2, 5, and 12 days
after GFS using the Affymetrix rat 230A GeneChip®. In our
current study we took samples only 14 days after surgery. This,
in general, mimics the day 12 sample in the rat study. Both the
12- and 14-day sampling times correlate with the latter stages
of the wounding response. Therefore, we would not only ex-
pect to find similarities between our rabbit 14-day and rat 12-
day results, but we would also expect to find gene expression
differences characteristic of a late wound stage, principally in
genes associated with the structural process of wound heal-
ing.
TGFB2 and connective tissue growth factor (CTGF) are
two growth factors that mediate the wound-healing process.
Their expression generally peaks early in the wound-healing
response. For both transcript levels in the rat [9] and protein
levels in rabbit [8], CTGF was found to reach peak expression
levels 5-7 days after surgery. In both cases CTGF expression
levels returned to presurgical levels by days 12-14. Like the
results from the rat microarray, we found no significant dif-
ference in CTGF expression on day 14 (Table 2). In our rat
GFS microarray study, we found the expression level of TGFB2
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TABLE 3. GENES WHOSE EXPRESSION WAS SIGNIFICANTLY (P LESS THAN OR EQUAL TO 0.05) ALTERED BY MORE THAN TWO-FOLD
                          Mean log2
 Probe name     p-value   difference          Hit definition           E-value     GO biological process term
-------------   -------   ----------   ----------------------------   ----------   --------------------------
UF_Oc_n_41285    0.001       4.48      Serum amyloid A-3 protein      0            Acute-phase response
UF_Oc_n_41565    0.007       3.11      Interleukin-1 beta       0                  Antimicrobial humoral
                                       (IL-1 beta)                                 response, inflammatory
                                                                                   response
UF_Oc_n_41308    0.020       2.81      Alpha-1-acid glycoprotein      0            Acute-phase response,
                                       (Orosomucoid)                               inflammatory response
UF_Oc_c_40013    0.000       2.07      Cathepsin K (EC 3.4.22.-)      0            Lysosome, proteolysis
                                                                                   and peptidolysis
UF_Oc_r_30389    0.012       1.87      Similar to Ldb1a               8.46E-37
UF_Oc_n_41283    0.008       1.85      92 kDa type IV collagenase     0            Collagen catabolism,
                                       (Matrix metalloproteinase-9)                collagenase activity
UF_Oc_c_40416    0.002       1.83      Neutrophil granules matrix     1.40E-20     Defense response, innate
                                       glycoprotein SGP28                          immune response,
                                                                                   cell-cell adhesion
UF_Oc_r_30382    0.003       1.74      Ceruloplasmin At 3.0           1.04E-38     oxidoreductase activity
                                       angstrom
UF_Oc_c_40419    0.042       1.37      Lumican                        5.93E-20     Collagen binding,
                                                                                   collagen fibril
                                                                                   organization
UF_Oc_c_40194    0.010       1.32      Lysozyme C (1,4-beta-          0            Lysozyme activity,
                                       N-acetylmuramidase C)                       response to bacteria,
                                                                                   cell wall catabolism
UF_Oc_n_31501    0.011       1.28      Fibronectin                    0            Acute-phase response,
                                                                                   inflammatory response,
                                                                                   cell adhesion and
                                                                                   migration, extracellular
                                                                                   matrix structural
                                                                                   constituent
UF_Oc_n_41531    0.016       1.20      Serum amyloid A-1              0            Acute-phase response
UF_Oc_c_40715    0.038       1.17      major facilitator family       1.18908
                                       transporter
UF_Oc_r_30531    0.003       1.11      Cathepsin B                    3.13E-06     Negative regulation of
                                                                                   inflammatory response,
                                                                                   proteolysis and
                                                                                   peptidolysis
UF_Oc_n_41428    0.020       1.05      Cathepsin E (EC 3.4.23.34)     0            Positive regulation of
                                                                                   cytokine secretion,
                                                                                   proteolysis and
                                                                                   peptidolysis
UF_Oc_c_40213    0.048       1.05      Lumican                        0            Collagen binding,
                                                                                   collagen fibril
                                                                                   organization
UF_Oc_n_41539    0.009       1.04      Cystatin B                     0
UF_Oc_c_40622    0.010      -1.00      NADH dehydrogenase subunit 4   0.335226
UF_Oc_n_41502    0.022      -1.05      Voltage-dependent anion        0            Mitochondrial outer
                                       channel 1                                   membrane
UF_Oc_n_41237    0.006      -1.06      Mono (ADP-ribosyl)             0
                                       transferase
UF_Oc_c_40346    0.040      -1.25      Corneal endothelium specific   6.09E-38
                                       protein 1
UF_Oc_n_41352    0.020      -1.35      Cytochrome P450 2A10           0            Electron transport,
                                       (CYPIIA10)                                  oxidoreductase activity
                                                                                   on paired donors, oxygen
                                                                                   binding
UF_Oc_r_30067    0.004      -1.52      Alpha-actinin-2-associated     0
                                       LIM protein
UF_Oc_c_40478    0.024      -1.66      Corneal endothelium specific   6.32E-09
                                       protein 1
UF_Oc_r_30565    0.006      -1.70      Hypothetical protein           0.00204271
UF_Oc_n_41489    0.008      -2.06      Chondromodulin-I (Leukocyte    0            Cell differentiation,
                                       cell-derived chemotaxin 1)                  extracellular space
Mean log2 difference is the level of gene expression in tissue surrounding the surgical site compared to similar tissue from the nonsurgically
treated control eye. The p-value represents the level of significance in treatment means, hit definition the name of the most homologous gene
and E-value the level of confidence that the matched name is incorrect. Also listed are the GeneOntology Consortium terms for biological
process associated with the most homologous gene.
170decreased 2.5 fold by day 12 [9]. In this study, the TGFB2
expression level decreased 71%, but this difference was not
significant.
In our rat GFS model, scar tissue began to form 7-14 days
after GFS [9]. Consistent with this scarring, we saw an in-
crease in the expression of genes which act as structural com-
ponents of the extracellular matrix. In particular, we found
the expression of various collagens, procollagens, biglycan,
fibronectin, lumican and vimentin to increase five days after
surgery [9]. Expression level of these genes was still elevated
on day 12. The results of our current study are, in general,
consistent with these results. On day 14, we found both lumican
and fibronectin had significantly increased (Table 2). Addi-
tionally, lysozyme, a gene thought to be directly involved with
the defense against bacteria [10,11], was significantly increased
in both the rat and rabbit microarray studies (Table 2). Finally,
in our current study MMP9 was one of the genes that increased
the most (Table 3). In the rat microarray study, however, MMP9
increased only on day 2 and 5 and was back to control levels
on day 12 [9]. A number of genes that changed the most on the
rabbit array (serum amyloid protein A-1 [SAA1], serum amy-
loid protein A-3 [SAA3], cystine-rich secretory protein-3
[CRISP3], and alpha-1-acid glycoprotein [AGP]) were not
present on the rat array, thus, no comparisons could be made
with these results.
The acute-phase response is an immediate set of nonspe-
cific host inflammatory responses to tissue injury, surgical
trauma, or infection. The response is characterized by the re-
lease of proinflammatory cytokines, particularly interleukin-
6 (IL6), tumor necrosis factor-alpha (TNFA), and IL1B, which
stimulate and mediate the hepatic synthesis and subsequent
release of acute-phase proteins (APP) into the blood steam
[12-14]. An APP has been defined as one whose plasma con-
centration changes by at least 25% during inflammation [14].
The concentration of some APP, however, is known to increase
by as much as 1,000 fold [13]. The systemic nature of this
response constitutes an innate immune response and the APP
function to restore homeostasis, neutralize pathogens and pro-
mote conditions necessary for tissue repair. APP production
in extrahepatic tissues has also been observed in many mam-
mal species and constitutes a local, rather than systemic, re-
sponse [12-15].
As further biological validation of our rabbit microarrays
we would expect to see changes in the expression of genes
associated with an acute-phase response, the repair of tissue,
and the defense against pathogens. We did find significant
changes in the expression of genes involved in the acute-phase
response. Of the three primary cytokines that helped mediate
this response, only IL1B, IL6 are represented on our rabbit
arrays. The expression of both increased significantly; ILB1
by 8.6 fold and IL6 by 13% (Table 2). The gene with the larg-
est increase in expression (22 fold), SAA3 and its family mem-
ber, SAA1, which increased 2.3 fold, are classified as acute-
phase reactants [13] (Table 3). Serum amyloid A consists of a
family of apolipoproteins that are highly conserved across all
vertebrates and are sensitive markers for inflammation
[12,14,16]. SAA3 is the predominant extrahepatic form in rats,
mice, and rabbits [12,17] and was required for effective stimu-
lation of collagenase by IL1B in rabbit corneal fibroblasts [18].
The transcript level of three other APP genes, AGP, ceru-
loplasmin (CP), and FN1 was significantly increased follow-
ing GFS. Both AGP, whose expression increased 7 fold, and
CP, whose expression increased 3.3 fold, are believed to act
as antiinflammatory and immunomodulatory agents (Table 3).
Therefore, it has been hypothesized that their extrahepatic
expression functions to reduce inflammatory induced tissue
damage [14,19,20].
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TABLE 4. REAL-TIME PCR RESULTS
             Transforming growth factor beta 2
-------------------------------------------------------
Sample   Green Signal   Red Signal   Array    Real-Time
------   ------------   ----------   ------   ---------
1A          73.9**         45.3       -1.38     0.77
2A          21.2            9*        -2.35     0.26
4A         850.6**         83.2      -10.20     0.04
7A         263.9**         43.7       -6.06     0.15
Mean                                  -5.00     0.31
               Matrix metalloproteinase 9
-------------------------------------------------------
Sample   Green Signal   Red Signal   Array    Real-Time
------   ------------   ----------   -----   ---------
1A          29.7          106.8       3.60    727.2
2A          18.4          158.9       8.64   1928.9
4A          26.2           69.8       2.67    574.4
7A          30.9          110.8       3.59   1020.4
Mean                                  4.62   1062.7
                    Interleukin-1 beta
-------------------------------------------------------
Sample   Green Signal   Red Signal   Array    Real-Time
------   ------------   ----------   -----   ---------
1A          14            254.8      18.25     86.03
2A           4.3*          50.4      11.69    258.92
4A           2*            11.1*      5.43     67.75
7A          17.2          306.1      17.82    146.83
Mean                                 13.3     139.9
                        Fibronectin
-------------------------------------------------------
Sample   Green Signal   Red Signal   Array    Real-Time
------   ------------   ----------   -----   ---------
1A           9.9*          24.8       2.50      5.68
2A           2.9*           6.1*      2.08      4.65
4A           4.3*          10.2*      2.36      5.36
7A          15.3           29.7       1.94      6.42
Mean                                  2.22      5.53
             Transforming growth factor beta 1
-------------------------------------------------------
Sample   Green Signal   Red Signal   Array    Real-Time
------   ------------   ----------   -----   ---------
1A           8.8           11.5       1.30      2.43
2A          10.3           18.2       1.77      1.64
4A          14.9           12.8      -1.16      1.46
7A          12             11.3      -1.06      6.91
Mean                                  0.21      3.11
Change in gene expression in tissue surrounding the surgical site
compared to similar tissue from the non-surgically treated control
eye based on real-time PCR (real-time) and microarrays (Array). Fold
change values are arithmetic and not logarithmic. Also listed are the
corresponding processed red and green signal values from the
microarrays. The asterisk denotes signal values that are indistinguish-
able from background values and the double asterisk indicates signal
values that are inordinately high.
171FN1 gene expression increased 2.5 fold following GFS
(Table 3). In humans, it appears that a single gene codes for
two distinct forms, cellular and plasma. The plasma form is
classified as an APP. The cellular form, however, is the major
cell surface glycoprotein of many fibroblast cell lines. A ma-
jor FN1 function is in the adhesion of cells to extracellular
matrix (ECM) materials, particularly collagen, and its pres-
ence is therefore instrumental in tissue repair [21]. We ob-
served the transcript expression level of two other ECM-asso-
ciated genes, lumican (LUM) and MMP9, to be increased af-
ter GFS. LUM increased 2.5 fold (Table 3). LUM is present in
large quantities in the corneal stroma, where it not only inter-
acts with collagen molecules to limit fibril growth, but also
plays a critical role in the regular spacing of fibrils and acqui-
sition of corneal transparency [22]. MMP9 expression, in-
creased 3.6 fold. MMP9 is an endoprotease that cleaves ma-
trix substrates, such as gelatin and collagen types IV, V, and
VII, and therefore, plays a major role in the alteration of the
ECM after tissue injury [23,24]. MMP9 was shown to be
upregulated at both the transcriptional and translational levels
by SAA in human THP1 cells [23]. Also of note is that MMP9
was found to be upregulated at both the mRNA and protein
level in mononuclear blood cells of normal-tension glaucoma
patients [24].
As with the increase in the expression of genes associ-
ated with the acute-phase response and tissue repair, we found
the expression of defense-related genes to increase. The ex-
pression of lysozyme C and CRISP3, which are principal en-
zymes of the innate immune system, increased 2.5- and 3.6
fold, respectively (Table 3). Lysozyme is a protein that de-
grades bacterial cell walls. It is a component of granules of
neutrophils and the major secretory product of macrophages
[10,11]. Similarly, CRISP3, which was originally purified from
human neutrophils, is present in the gelatinase granules of
human neutrophils, along with lysozyme, collagenase, and
gelatinase [25].
It is clear that our rabbit microarrays are providing gene
expression results that are compatible with those found in simi-
lar tissue injury, wound healing and GFS surgery studies. For
example, the genes that changed the most, SAA1, SAA3 AGP,
and FN1 are acute-phase reactants. If not directly involved,
they are at least markers for inflammation. Other genes show-
ing large changes include IL1B, which is known to mediate
inflammatory responses, LUM and MMP9, which are associ-
ated with degradation and/or remodeling of the ECM, and both
lysozyme and CRISP3 which are implicated as a direct de-
fense against pathogenic challenge. Our microarray results are
also generally consistent with the magnitude and direction of
real-time PCR results when microarray signal values are well
above background levels.
The availability of rabbit microarrays affords a new and
unique opportunity for identifying molecular controls for ocu-
lar processes. An addition benefit is that these microarrays
have been successfully used for a nonophthalmic study in-
volving vascular tissue (Dr. Scott Berceli, personal communi-
cation). Fortunately, relatively few genes exhibit tissue-spe-
cific expression, and therefore, fulfill a similar function in dif-
ferent cell types. Thus, gene-expression and associated cellu-
lar behavior and responses across multiple tissue types, in-
cluding epithelial, connective, neurological, and immunologic,
may potentially be investigated using this technology, imply-
ing a utility for more than ocular research alone. The greatest
limitation of these microarrays is that they only represent ap-
proximately 3000 unique genes. Further sequencing is under-
way to obtain a greater coverage of the expressed rabbit ge-
nome. This will no doubt, enhance the utility of the rabbit
microarrays.
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